TABLE 1.
Patient Demographics and Baseline Disease Characteristics in Patients Who Received Glofitamab at Any Dose and at the RP2D (Safety-Evaluable Patients)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.